A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Open to people ages 2 years and up

• The participant must have a clinical diagnosis of PROS or a malformation within the ISSVA classification.
• One or more documented activating PIK3CA mutation(s) that are targeted by selective PI3Kα inhibitors in lesional tissue and/or cell-free DNA from the lesion or blood. Some participants may be eligible without a documented PIK3CA mutation as long as no other genetic driver has been documented.
• Lansky (<16 yo) or Karnofsky (≥16 yo) performance status of ≥50.
• Agree to provide archived lesional fluid and/or tissue or be willing to undergo pretreatment lesional biopsy (if considered safe and medically feasible) to assess PIK3CA status.

• History of hypersensitivity to PI3K inhibitors.
• Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
• Clinically significant, uncontrolled cardiovascular disease
• Received disease-directed therapy prior to the first dose of study drug:
  1. Systemic therapy or antibody within 5 half-lives of the therapy.
  2. Local therapy including radiation, surgery, or other procedures within 28 days; lesion(s) must have demonstrated progression after the procedure.